Wegovy vs. Zepbound: Comparing the Two Leading Weight Loss Injections

Wegovy vs. Zepbound: Comparing the Two Leading Weight Loss Injections

By Dr. Onikepe Adegbola, MD PhD

Two medications now dominate the GLP-1 weight loss conversation: Wegovy and Zepbound. Both produce significant weight loss. Both are FDA-approved specifically for chronic weight management. And both leave patients asking the same question — which one is better for me?

I prescribe both regularly at Mochi Health, and the honest answer is that neither is universally superior. They work through different mechanisms, produce different magnitudes of weight loss on average, and have different side effect profiles. The right choice depends on your body, your goals, and your tolerance.

Here's a straightforward comparison based on clinical trial data and what I observe in practice.

How Wegovy and Zepbound Work: The Mechanism Difference

This is the fundamental distinction, and it matters more than most side-by-side comparisons acknowledge.

Wegovy (Semaglutide)

Wegovy activates GLP-1 receptors. That's its single mechanism. GLP-1 receptor activation does several things: it stimulates insulin secretion (glucose-dependent, so it doesn't cause dangerous lows in non-diabetics), suppresses glucagon, slows gastric emptying, and — most relevantly — acts on the brain's appetite centers to reduce hunger and increase satiety.

The maximum dose is 2.4 mg weekly. At this dose, the STEP trial program demonstrated average body weight reductions of 15-17% over 68 weeks.

Zepbound (Tirzepatide)

Zepbound activates both GIP and GLP-1 receptors. GIP (glucose-dependent insulinotropic polypeptide) was historically associated with fat storage, but newer research reveals that pharmacological GIP receptor activation actually enhances weight loss — potentially by improving fat tissue metabolism and amplifying the appetite-suppressive effects of GLP-1 signaling.

The maximum dose is 15 mg weekly. In the SURMOUNT clinical trials, patients on tirzepatide at the highest dose lost an average of 20-25% of their body weight over 72 weeks.

The dual mechanism of Zepbound appears to produce more weight loss on average. But averages obscure individual variation. Some patients respond dramatically to semaglutide and modestly to tirzepatide. Bodies are not uniform in their responses.

Weight Loss Results: Wegovy vs. Zepbound

Let me put the trial data side by side. Keep in mind these are cross-trial comparisons (different study populations, slightly different designs), not a direct randomized comparison between Wegovy and Zepbound in the same trial.

• Wegovy (STEP 1 trial): 16.9% average body weight loss with semaglutide 2.4 mg vs. 2.4% with placebo at 68 weeks. About one-third of patients lost 20% or more of their body weight.
• Zepbound (SURMOUNT-1 trial): 22.5% average body weight loss with tirzepatide 15 mg vs. 3.1% with placebo at 72 weeks. Over half of patients on the highest dose lost 20% or more of their body weight.

The difference is clinically meaningful. For a 250-pound person, 17% weight loss is about 42 pounds. 22.5% weight loss is about 56 pounds. That's a 14-pound gap, which matters.

But here's the nuance. Not everyone reaches the maximum dose. Side effects, insurance requirements, or clinical judgment may keep some patients at lower doses. At comparable "mid-range" doses, the gap between Wegovy and Zepbound narrows. And individual response variability means some patients on Wegovy will outperform some patients on Zepbound.

Side Effect Comparison

The GI side effect profiles of Wegovy and Zepbound are remarkably similar. Both medications work on the gut, and both cause dose-dependent GI effects that typically peak during dose escalation and improve over time.

Nausea

Reported in approximately 44% of Wegovy patients and 26-33% of Zepbound patients across trials. Wegovy's higher nausea rate may partly reflect its faster dose escalation schedule or differences in trial design. In practice, I find that patients on either medication benefit from the same anti-nausea strategies: small meals, bland foods during adjustment, adequate hydration.

Diarrhea

Similar rates: approximately 30% with Wegovy and 21-25% with Zepbound. Both medications alter gut motility, which can produce looser stools, urgency, or increased frequency — especially during the first few weeks at each new dose.

Constipation

Approximately 24% with Wegovy and 11-17% with Zepbound. Both slow gastric emptying, which can slow overall gut transit and harden stools. Fiber, hydration, and movement help manage this.

Overall Tolerability

In the clinical trial programs, discontinuation rates due to adverse events were slightly lower with tirzepatide than semaglutide, suggesting modestly better tolerability. But individual experience varies widely. Some patients tolerate Wegovy perfectly and struggle with Zepbound, and vice versa.

Regardless of which medication you take, GI side effects are the primary challenge for most patients. Supporting digestive health during treatment makes a real difference in tolerability and adherence. Casa de Sante GLP-1 supplements are designed for exactly this purpose — formulated for sensitive stomachs to help patients stick with their treatment plan.

Cardiovascular and Long-Term Outcomes

Wegovy currently has stronger published cardiovascular outcome data. The SELECT trial — a landmark study of over 17,000 patients — demonstrated that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% compared to placebo in patients with established cardiovascular disease and obesity but without diabetes.

This is a big deal. It means Wegovy isn't just a weight loss drug — it has proven cardiovascular protective effects independent of its metabolic benefits.

Zepbound doesn't yet have a comparable published cardiovascular outcome trial specifically for its weight management indication, though the SURPASS-CVOT trial studying tirzepatide's cardiovascular effects in diabetic patients has generated positive signals. As additional long-term data emerges, the cardiovascular comparison may shift.

For patients with established cardiovascular disease or high cardiovascular risk, the SELECT trial data gives Wegovy a distinct evidence advantage at this point in time.

Practical Considerations: Cost, Access, and Insurance

Clinical superiority means nothing if you can't access or afford the medication. In practice, the Wegovy vs. Zepbound decision is often made by insurance formularies rather than clinical preference.

Insurance Coverage

• Some plans cover Wegovy but not Zepbound (or vice versa)
• Some plans cover the diabetes versions (Ozempic/Mounjaro) but not the weight loss versions
• Prior authorization requirements differ between medications and insurers
• Medicare currently does not cover anti-obesity medications in most circumstances

Cost Without Insurance

Both medications carry retail prices over $1,000 per month without insurance. Manufacturer savings programs exist for both: the Wegovy savings offer and the Zepbound savings card. Eli Lilly has also introduced a Zepbound vial program at lower price points for self-pay patients. Novo Nordisk has responded with competitive pricing initiatives for Wegovy.

Supply

Both medications have experienced supply constraints since launch. As of 2026, availability has improved but intermittent shortages at specific dose levels still occur. Check with your pharmacy before assuming consistent supply.

How to Choose: Wegovy or Zepbound

Based on my clinical experience, here's when I lean toward each:

Consider Wegovy if:

• You have established cardiovascular disease (the SELECT trial evidence is compelling)
• Your insurance covers Wegovy but not Zepbound
• You've responded well to semaglutide in the past (Ozempic or Rybelsus)
• Long-term safety data is a priority for your decision-making

Consider Zepbound if:

• Maximum weight loss is your primary goal
• You haven't had adequate response to GLP-1 monotherapy
• Your insurance covers Zepbound or you're using a self-pay option
• You're looking for a dual-mechanism approach (GIP + GLP-1)

This isn't a permanent decision. Patients can switch between medications if one isn't working or is poorly tolerated. Discuss the options with your prescribing provider — they'll consider your medical history, comorbidities, insurance, and goals when recommending one over the other.

Frequently Asked Questions

Can I switch from Wegovy to Zepbound (or vice versa)?

Yes. Switching between semaglutide and tirzepatide is done routinely. Your provider will typically start you at a lower dose of the new medication and titrate up, even if you were at a high dose of the previous one. The two drugs have different receptor profiles, so your body needs time to adjust regardless of prior GLP-1 exposure.

Is Zepbound always better for weight loss than Wegovy?

On average, yes — clinical trials show greater weight loss with tirzepatide than semaglutide. But individual results vary widely. Some patients achieve exceptional weight loss on Wegovy. The averages describe populations, not individuals. Try one, assess your response, and adjust if needed.

Do Wegovy and Zepbound interact with the same medications?

Both medications slow gastric emptying, which can affect the absorption timing of other oral medications. This is clinically relevant for medications with narrow therapeutic windows (like warfarin or levothyroxine). Inform your prescriber about all medications you take so they can monitor for interactions and adjust timing if needed.

Which has fewer side effects, Wegovy or Zepbound?

Clinical trials suggest slightly better GI tolerability with tirzepatide (Zepbound) compared to semaglutide (Wegovy), with lower rates of nausea and discontinuation due to adverse events. However, both medications produce GI side effects in a substantial minority of patients, and individual tolerance is unpredictable until you try the medication.